SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending as investors discuss its potential for a short squeeze and future growth, fueled by news of Goldman Sachs taking a significant stake in the company. Community members are actively debating the impact of upcoming warrants and a possible shift in market sentiment, while also highlighting the company's potential within the evolving real estate landscape. Bullish sentiment appears to be growing, with many looking ahead to earnings.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave ($CRWV) is trending as investors anticipate upcoming earnings, with discussions focusing on revenue beats versus EPS concerns due to ongoing capital expenditures. Community sentiment is mixed, with some expressing long-term bullishness while others are wary of a potential negative earnings reaction and insider selling. The stock's volatility and the broader AI data center sector are also key talking points.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending amid discussions around upcoming earnings and the potential impact of ACA subsidy changes. Community members are weighing the potential benefits of a shift towards individual health savings accounts, while others express concern over the stock's performance and reliance on ACA. Traders are closely watching for key levels and potential catalysts that could drive the stock's next move.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the potential for profitability amid delivery numbers and JPMorgan's reduced holdings. The community is actively debating market manipulation and whether NIO's management is effectively rewarding long-term investors. There are also discussions around NIO's battery swap technology and its competitive positioning against companies like XPEV, Tesla and BYD.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors anticipate upcoming earnings and data from the Phase 3 HOPE-3 trial, which is expected to be released soon. Community members are actively discussing the potential for a short squeeze and speculate on the impact of the data on FDA approval. Some are expressing concerns about management strategy while others remain confident in the company's prospects, particularly given recent developments with competitor Sarepta.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await the outcome of an oral explanation meeting with the EMA regarding its Alzheimer's drug, Blarcamesine, with potential approval news expected soon. Community discussions revolve around speculation on who will present at the meeting and the impact of the oral explanation on approval odds, with some expressing concerns about the recent stock decline. Despite the uncertainty, many remain optimistic about the drug's potential and are anticipating a decision.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

GALT is experiencing increased interest fueled by upcoming presentations at the AASLD Liver Meeting, where new biomarker data and trial results will be shared. The community is actively discussing the potential of Belapectin, particularly its use in combination with GLP-1 drugs, and the possibility of a short squeeze due to the stock's high short interest. Speculation around a potential partnership or buyout before the year-end is also contributing to the current buzz.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending amidst discussions about its recent price volatility and the impact of broader market conditions. Community members are debating its long-term potential in AI infrastructure, with some pointing to misinformation surrounding earnings while others see it as a buying opportunity after a significant pullback. The stock's sensitivity to market fluctuations and potential manipulation are also hot topics.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending downwards as the community discusses concerns around debt, insider selling, and the feasibility of AI initiatives following a large post-earnings surge. Investors are closely watching management's response to market skepticism and rumors, with some expressing frustration over the lack of communication. There's also chatter about the stock potentially filling a gap and what this could mean for future price movement.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as investors anticipate upcoming earnings, with the community debating whether the recent surge indicates a top or a buying opportunity. Discussions revolve around analyst upgrades and the potential impact of AI infrastructure demand, while some traders are closely watching Michael Burry's short position. The stock's reaction to resistance levels and implied volatility is also a key focus for many.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aquestive Therapeutics (NASDAQ:AQST) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus...

Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Aquestive Therapeutics (AQST) This Year?

Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Aquestive Therapeutics jumped more than 11% in after-hours trading Thursday after CEO Dan Barber said the company’s oral epinephrine film, Anaphylm, could become a “blockbuster” drug with as much as $1 billion in peak global sales.Barber&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/09/25/aquestive-ceo-on-its-potential-1-billion-blockbuster-product.html">said in an interview</a> on CNBC’s "Mad Money" with Jim Cramer, noting that despite winning six FDA approvals and distributing 2.5 billion doses worldwide over the past two decades, Aquestive has historically remained small, with annual revenue of $50 million to $70 million.&nbsp;He said Anaphylm, designed to treat severe allergic reactions with a dissolvable sublingual film instead of an auto-injector, represents the company’s first chance at a broad-market product.Cramer, who first highlighted the stock earlier this month as a speculative pick, pointed to Anaphylm’s potential as an alternative to epinephrine auto-injectors like the EpiPen.Earlier this month, Aquestive said that the FDA has determined an advisory committee meeting is not required for Anaphylm, maintaining the Prescription Drug User Fee Act target action date of January 31, 2026.&nbsp;Oppenheimer raised its price target on Aquestive to $8 from $7 following the announcement, reiterating its ‘Outperform’ rating and noting that investors interpret the FDA decision as increasing the chances of approval.The company has also outlined its regulatory strategy outside the U.S., saying in July that Health Canada granted a meeting to discuss its planned New Drug Submission for Anaphylm and that an initial briefing package has been submitted to the European Medicines Agency.&nbsp;Aquestive said Canada and Europe represent “ideal initial international markets” for the drug, given regulatory alignment and patient need.To prepare for a potential launch, Aquestive has raised about $160 million in financing, which Barber said positions the company to ensure broad outreach to providers, caregivers, and patients once the FDA decision is made.On Stocktwits, retail sentiment for Aquestive was ‘bullish’ amid ‘high’ message volume.One user said that Barber’s appearance on&nbsp;CNBC’s “Mad Money” show&nbsp;was a turning point for Aquestive Therapeutics, saying the CEO “really painted the company in a great light” by backing up Anaphylm’s projected value with current epinephrine market data.&nbsp;<stembedurl>https://stocktwits.com/YaBoyJ313/message/630079945</stembedurl>Another user suggested that Aquestive could become a buyout target within two years of Anaphylm sales, predicting the stock could climb from about $10 to $25 if that scenario&nbsp;were to play out.<stembedurl>https://stocktwits.com/ImPoorAndHungry/message/630067707</stembedurl><a href="https://stocktwits.com/symbol/AQST">Aquestive’s stock</a> has risen 47.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aquestive’s stock (AQST) has risen 47.8% so far in 2025. (Photo credit: Getty Images)

Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate

Aquestive’s Anaphylm has drawn heightened investor attention after the CEO spotlighted it as the company’s first broad-market product.

Why Aquestive Therapeutics Stock Jumped After-Hours Today

Equity

Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

$NVDA

$MSFT

$AAPL

$GOOGL

Which of these Mag 7 stocks are you most bullish on right now?

AQST
Aquestive Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AQST News

AQSTAquestive Therapeutics Inc